Praxis Precision Medicines (PRAX) -- Resilience Amid Market Pullback | Janus Henderson Global Life Sciences Fund Q3 2026
· gurufocus.com
Stock performance was negatively impacted by a broader pullback in biotech stocks.Strong first-half returns were followed by reduced exposure from specialist in
Praxis Precision Medicines PRAX was noted in the Janus Henderson Global Life Sciences Fund Q3 2026 letter as a stock that faced challenges due to a broader pull...